Patents Represented by Attorney Rekha P. Bansal

Find this attorney in the Justia Lawyer Directory

  • 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use
    Patent number: 7662811
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: February 16, 2010
    Assignee: Amgen Inc.
    Inventors: Benny C. Askew, Jr., Toshihiro Aya, Kaustav Biswas, Guolin Cai, Jian J. Chen, Nianhe Han, Qingyian Liu, Thomas Nguyen, Nobuko Nishimura, Rana Nomak, Tanya Peterkin, Wenyuan Qian, Kevin Yang, Chester Chenguang Yuan, Jiawang Zhu, Derin C. D'Amico, Jason B. Human, Qi Huang
  • Triazoles and methods of use
    Patent number: 7612060
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: November 3, 2009
    Assignee: Amgen Inc.
    Inventors: Toshihiro Aya, Guolin Cai, Jian J. Chen, Derin D'Amico, Thomas Nguyen, Wenyuan Qian
  • Glycine transporter-1 inhibitors
    Patent number: 7538114
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: May 26, 2009
    Assignee: Amgen Inc.
    Inventors: Stephen Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • B1 bradykinin receptor antagonists
    Patent number: 7414134
    Abstract: The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: August 19, 2008
    Assignee: Amgen Inc.
    Inventors: Benny C. Askew, Jr., Jian J. Chen, Derin C. D'Amico, Thomas Nguyen, Kevin Yang